12/22/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Siklos

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
3 3
3 3

Hydroxikarbamid

Hydroxikarbamid

Klass : 3

Visa all info

Skriv ut

Kontakta oss

  1. Ngu SF, Ngan HY. Chemotherapy in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016;33(0):86-101.

  2. Boere I, Lok C, Vandenbroucke T, Amant F. Cancer in pregnancy: safety and efficacy of systemic therapies. Curr Opin Oncol. 2017;29(5):328-334.

  3. Lambertini M, Peccatori FA, Azim HA. Targeted agents for cancer treatment during pregnancy. Cancer Treat Rev. 2015;41(4):301-9.

  4. Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Network of French Pharmacovigilance Centers et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66(5):1101-10.

  5. United Kingdom Teratology Information Services (UKTIS). Methotrexate in pregnancy. 2016. Tillgänglig från: www.toxbase.com. Hämtad: 2018-06-15

  6. Arnon J, Meirow D, Lewis-Roness H, Ornoy A. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update. 2001;7(4):394-403.

  7. Haggar FA, Pereira G, Preen D, Holman CD, Einarsdottir K. Adverse obstetric and perinatal outcomes following treatment of adolescent and young adult cancer: a population-based cohort study. PLoS One. 2014;9(12):e113292.

  8. Dohle GR. Male infertility in cancer patients: Review of the literature. Int J Urol. 2010;17(4):327-31.

  9. Scialli AR, Bailey G, Beyer BK, Bøgh IB, Breslin WJ, Chen CL et al. Potential seminal transport of pharmaceuticals to the conceptus. Reprod Toxicol. 2015;58(0):213-21.

  10. Klemmt L, Scialli AR. The transport of chemicals in semen. Birth Defects Res B Dev Reprod Toxicol. 2005;74(2):119-31.

  11. Briggs G, Towers CV, Forinash AB. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 12th ed; 2021.

  12. Reprotox. Hydroxyurea. Micromedex [www]. [cited 2023-05-12].

  13. Schardein JL. Chemically Induced Birth Defects. Marcel Dekker Inc., New York and Basel. 1985.

  14. Gwer SO, Onyango KO. Prevalence and Incidence of Congenital Anomalies Amongst Babies Born to Women With Sickle Cell Disease and Exposed to Hydroxyurea During Pregnancy: A Systematic Review Protocol. JBI Database System Rev Implement Rep. 2018;16(5):1135-40.

  15. Liebelt EL, Balk SJ, Faber E et al. NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea. Birth Defects Res B Dev Reprod Toxicol. 2007;80:259-366.

  16. de Montalembert M, Voskaridou E, Oevermann L, Cannas G, Habibi A, Loko G et al. Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study. Am J Hematol. 2021;96(10):1223-1231.

  1. Ngu SF, Ngan HY. Chemotherapy in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016;33(0):86-101.
  2. Boere I, Lok C, Vandenbroucke T, Amant F. Cancer in pregnancy: safety and efficacy of systemic therapies. Curr Opin Oncol. 2017;29(5):328-334.
  3. Lambertini M, Peccatori FA, Azim HA. Targeted agents for cancer treatment during pregnancy. Cancer Treat Rev. 2015;41(4):301-9.
  4. Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Network of French Pharmacovigilance Centers et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66(5):1101-10.
  5. United Kingdom Teratology Information Services (UKTIS). Methotrexate in pregnancy. 2016. Tillgänglig från: www.toxbase.com. Hämtad: 2018-06-15
  6. Arnon J, Meirow D, Lewis-Roness H, Ornoy A. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update. 2001;7(4):394-403.
  7. Haggar FA, Pereira G, Preen D, Holman CD, Einarsdottir K. Adverse obstetric and perinatal outcomes following treatment of adolescent and young adult cancer: a population-based cohort study. PLoS One. 2014;9(12):e113292.
  8. Dohle GR. Male infertility in cancer patients: Review of the literature. Int J Urol. 2010;17(4):327-31.
  9. Scialli AR, Bailey G, Beyer BK, Bøgh IB, Breslin WJ, Chen CL et al. Potential seminal transport of pharmaceuticals to the conceptus. Reprod Toxicol. 2015;58(0):213-21.
  10. Klemmt L, Scialli AR. The transport of chemicals in semen. Birth Defects Res B Dev Reprod Toxicol. 2005;74(2):119-31.
  11. Briggs G, Towers CV, Forinash AB. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 12th ed; 2021.
  12. Reprotox. Hydroxyurea. Micromedex [www]. [cited 2023-05-12].
  13. Schardein JL. Chemically Induced Birth Defects. Marcel Dekker Inc., New York and Basel. 1985.
  14. Gwer SO, Onyango KO. Prevalence and Incidence of Congenital Anomalies Amongst Babies Born to Women With Sickle Cell Disease and Exposed to Hydroxyurea During Pregnancy: A Systematic Review Protocol. JBI Database System Rev Implement Rep. 2018;16(5):1135-40.
  15. Liebelt EL, Balk SJ, Faber E et al. NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea. Birth Defects Res B Dev Reprod Toxicol. 2007;80:259-366.
  16. de Montalembert M, Voskaridou E, Oevermann L, Cannas G, Habibi A, Loko G et al. Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study. Am J Hematol. 2021;96(10):1223-1231.